Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Regencell Bioscience Holdings Limited RGC NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • HK • USD

SharesGrow Score
53/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Regencell Bioscience Holdings Limited (RGC) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is neutral — 4 Hold.

RGC Analyst Ratings

Hold
4
Ratings
4 Hold
Based on 4 analysts giving stock ratings to Regencell Bioscience Holdings Limited in the past 3 months
Rating breakdown
Hold
4 100%
0%
Buy
0 analysts
100%
Hold
4 analysts
0%
Sell
0 analysts

People Also View

PBH
PBH
Prestige Consumer Healthcare Inc.
$56.66
-0.32%
 PAHC
PAHC
Phibro Animal Health Corporation
$59.02
-0.94%
 ANIP
ANIP
ANI Pharmaceuticals, Inc.
$78.29
-0.03%
 COLL
COLL
Collegium Pharmaceutical, Inc.
$35.64
+0.06%
 PROC
PROC
Procaps Group S.A.
$1.01
+100.00%
 SSIC
SSIC
Silver Spike Investment Corp.
$10.74
+1.27%
 HEXO
HEXO
HEXO Corp.
$0.71
+2.45%
 RAMMF
RAMMF
RAMM Pharma Corp.
$0.06
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message